Exelixis' Cometriq gets breakthrough designation in RCC

Exelixis Inc. (NASDAQ:EXEL) said FDA granted breakthrough therapy designation to Cometriq cabozantinib as second-line treatment for advanced renal cell carcinoma (RCC).

The company also said Monday that data from the Phase III METEOR study of Cometriq to treat RCC will be presented at next month's European Cancer Congress (ECC) meeting in Vienna. In July, the spectrum-selective kinase inhibitor of VEGF receptor 2 ( KDR/Flk-1; VEGFR-2) and c-Met receptor tyrosine kinase (c-MET; MET; HGFR; c-Met proto-oncogene) met METEOR's primary endpoint. ...